RNA aptamers selected against DNA polymerase β inhibit the polymerase activities of DNA polymerases β and κ

Leonid V. Gening1,2, Svetlana A. Klincheva2, Anastasia Reshetnjak2, Arthur P. Grollman1 and Holly Miller1,*

1Laboratory of Chemical Biology, Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY 11794-8651, USA and 2Institute of Molecular Genetics, Russian Academy of Sciences, Moscow 123182, Russia

Resubmitted April 10, 2006; Revised and Accepted April 13, 2006

ABSTRACT
DNA polymerase β (polβ), a member of the X family of DNA polymerases, is the major polymerase in the base excision repair pathway. Using in vitro selection, we obtained RNA aptamers for polβ from a variable pool of 8 × 10^12 individual RNA sequences containing 30 random nucleotides. A total of 60 individual clones selected after seven rounds were screened for the ability to inhibit polβ activity. All of the inhibitory aptamers analyzed have a predicted tri-lobed structure. Gel mobility shift assays demonstrate that the aptamers can displace the DNA substrate from the polβ active site. Inhibition by the aptamers is not polymerase specific; inhibitors of polβ also inhibited DNA polymerase κ, a Y-family DNA polymerase. However, the RNA aptamers did not inhibit the Klenow fragment of DNA polymerase I and only had a minor effect on RB69 DNA polymerase activity. Polβ and κ, despite sharing little sequence similarity and belonging to different DNA polymerase families, have similarly open active sites and relatively few interactions with their DNA substrates. This may allow the aptamers to bind and inhibit polymerase activity. RNA aptamers with inhibitory properties may be useful in modulating DNA polymerase activity in cells.

INTRODUCTION
DNA polymerases (pols) replicate and maintain the integrity of cellular DNA. As a consequence, DNA pols may play key roles in both the avoidance and development of cancer (1). In addition, since DNA pols are the target of many chemotherapeutic agents, they may influence the efficacy of the treatment and possibly the development of resistance (1). DNA polymerase β (polβ), a member of the X-family of low fidelity DNA pols, is the major gap-filling polymerase in both short and long patch base excision repair (BER) pathways (2). Polβ is a distributive enzyme on long single-stranded templates (3) but acts processively on a gapped substrate (4). Tumors and tumor cell lines where polβ has been deleted or truncated have decreased polβ activity and therefore impaired BER (5,6). It has been suggested that decreased polβ activity increases the susceptibility of individuals to cancer (7). High expression of polβ has been seen in tumor cell lines and is associated with increased mutagenicity, genetic instability and tumorigenesis (8–10). Increased polβ activity also has been shown to increase tolerance to several chemotherapeutic agents including radiation, cisplatin and alkylating agents (8,11,12). The Y-family of DNA polymerases are characterized by low fidelity and are thought to be important in DNA damage tolerance pathways that involve translesion synthesis (13,14). However, increased or uncontrolled expression of error-prone DNA polymerases could lead to mutations and cancer (1). In fact, alteration of Y-family polymerase expression levels appears to be common in tumors (1). Although it is not clear whether overexpression of a Y-family polymerase is causative in the initiation or progression of tumorigenesis, high expression of certain DNA pols may provide cells with a growth advantage and/or resistance to DNA damaging agents. In view of the tremendous importance DNA pols play in human disease, the ability to modulate DNA polymerase activity in cells would provide increased understanding of their important role and could lead to the development of new therapies.

RNA aptamers are RNA oligomers that bind tightly and specifically to target molecules. Aptamers are selected in vitro via SELEX (systematic evolution of ligands by exponential enrichment) from randomized RNA libraries (15,16). RNA aptamers are currently being developed as possible...
therapeutic agents; e.g. RNA aptamers specific for human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) have been explored as potential RT inhibitors to inhibit HIV-1 replication (17–19). We decided to select RNA aptamers that would bind specifically to and inhibit the activity of a DNA polymerase. Owing to the natural affinity the polymerase has for nucleic acids, we expected that the aptamers would bind to the polymerase active site and be highly specific inhibitors of enzymatic activity. We report here the selection and characterization of RNA aptamers selected to inhibit the polymerase activity of polβ. Unexpectedly, the aptamers also bind to and inhibit DNA polymerase κ. These semi-selective RNA aptamers that inhibit error-prone repair polymerases could prove useful for understanding the role of repair in the initiation and progression of cancer as well as in the development of resistance to chemotherapeutic DNA damaging agents.

MATERIALS AND METHODS

Oligonucleotides, RNA pools and target RNA

Template DNA for the RNA pool and PCR primers were synthesized on a model 394 Applied Biosystems automated DNA synthesizer. The preparation of the random RNA pool has been described previously and shown to be a suitable library for automatic SELEX (20). Briefly, templates for reverse transcription were synthesized by PCR using synthetic oligonucleotides. The template was 5'-GGGAATGGATCC-ACATCTACGAATTCT-30N—TTCATCGAGACCTTGAAGAAGCTT-3', where 30N represents 30 random nucleotide positions. PCR primers were 5'-GATAATCGACTCATA TAGGGAAATGGATCCCATCTACGA-3' and 5'-AAGCTTTCGTCAAGTCTGCAGTA-3', where the T7 promoter sequence is underlined. RNA pools were prepared by in vitro transcription with T7 RNA polymerase (Stratagene, La Jolla, CA, USA). Pool RNAs were refolded by heat denaturing at 73°C and rapidly cooling to room temperature in binding buffer (BB; 20 mM Tris–HCl, pH 7.7, 120 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1 mM CaCl2).

Protein purification

DNA pols β (21) and κ (22) were purified from over-expressed Escherichia coli as previously described.

In vitro selection

To select the aptamers that bind to polβ, seven rounds of selection were performed. The aptamers were selected from the random pool of the RNA sequences described above. The first four rounds of selection were carried out by filtration of the polβ/RNA complex through nitrocellulose filters (0.45 μm HA; Millipore, Billerica, MA, USA). The filters were washed with BB as described (23). Bound material recovery from the filters, reverse transcription, PCR amplification of synthesized cDNA and RNA synthesis for the next round of selection were performed as described (23). Binding of the initial RNA pool to polβ was close to the background. In the first round of selection, 100 pmol (200 nM) polβ was incubated with 1.2 nmols (2.4 μM; 8 x 10^12 individual molecules) of variable RNA pool in 500 μl BB (Table 1). In the next three rounds of selection, the amount of the RNA was reduced to 500 pmol with the other conditions remaining the same. In the fifth and sixth rounds of selection on nitrocellulose filters, the background binding of the selected pool increased by >20%. Therefore, we went back to the pool from the fourth round of selection and performed the next three rounds of selection with polβ adsorbed to the surface of the immunological plates (Nunc Micro Well Module, Nalgene Nunc, Rochester, NY, USA) (24). In the fifth and sixth rounds, wells were coated for 1 h at room temperature with 50 pmol polβ in 200 μl of PBS. After blocking with Super Block Dry Blend (TBS) Blocking Buffer (Pierce Chemical company, Rockford, IL, USA) (24) and washing with BB, 200 μl of BB containing 150 pmol of the RNA pool from the previous round was introduced into the wells (Table 1). The wells were washed, bound RNA was recovered and cDNA synthesized as described (24). In the seventh round, the amount of polβ introduced into the well was reduced to 35 pmols (Table 1). The PCR products synthesized after seventh round of selection were cloned into the plasmid pGM-T (Promega, Madison WI, USA). Plasmid DNA was purified (Miniprep Kit, Qiagen, Valencia, CA, USA) and the sequence of the insert determined by automated sequencing.

Determination of the affinity of selected pools

After completion of rounds 4–7, each pool was assayed for its ability to bind polβ. RNA pools were radiolabeled in a reaction containing 40 mM Tris–HCl (pH 7.9), 25 mM MgCl2, 30 mM DTT, 2 mM each rNTP, 50 nM [α-32P]UTP, 40 U of RNase inhibitor (Roche Applied Science, Indianapolis, IN, USA), 120 U of T7 RNA polymerase (Stratagene, La Jolla, CA, USA) and 45 pmol purified PCR product in a total reaction volume of 100 μl (PCR Cleanup Kit, Qiagen, Valencia, CA, USA). After 1 h of incubation at 37°C, the labeled RNA was purified by electrophoresis on an 8% denaturing polyacrylamide gel (PAG) (23). Rather than determining the binding constants of selected pools we determined the minimal concentrations of polβ at which the binding of the complex of labeled RNA with protein was detectable. After the fourth round of selection the binding was minimally detectable at 100 nM polβ. After the sixth round, binding was detectable at 30 nM polβ. After the seventh round binding was well above background at 30 nM polβ. The pool selected after the eighth round had similar binding to polβ as the pool after the seventh round, so we cloned the PCR products obtained after seventh round of selection.
Preparation of individual RNA aptamers for in vitro analysis

Individual RNA aptamers were synthesized by in vitro transcription from PCR products obtained by the direct amplification of bacterial lysates (25). In vitro transcription reactions were performed in a mixture containing: 40 mM Tris–HCl (pH 7.9), 25 mM MgCl₂, 30 mM DTT, 1 mM each rNTP, 40 U of RNAse inhibitor (Roche Applied Science, Indianapolis, IN, USA), 200 U of T7 RNA polymerase (Stratagene, La Jolla, CA, USA) and 70 pmol of purified (PCR Cleanup Kit, Qiagen, Valencia, CA, USA) PCR product. The mixture was incubated overnight at 37°C and the synthesized RNA was purified by electrophoresis as described (23). After elution from denaturing PAGE, the RNA was ethanol precipitated and resuspended in 20 µl of H₂O. Then 2 µl of 1M NaCl was added, and the mixture was incubated for 3 min at 73°C and cooled to room temperature. RNA concentration was determined using yeast transfer RNA (tRNA) (Roche Applied Science, Indianapolis, IN, USA) as a standard (1 OD tRNA = 42 µg). The RNA was diluted in loading buffer (95% formamide, 0.1% xylene cyanol 10 mM Na-EDTA) and electrophoresed on a 10% denaturing PAGE. The gel was stained with CYBR Green II and the amounts of RNA quantified using a Storm 840 phosphorimager (Amersham Biosciences Corp., Piscataway, NJ, USA) and ImageQuant.

Kₜ determination of individual RNA aptamers

Individual RNA aptamers were radiolabeled in 40 mM Tris–HCl (pH 7.9), 25 mM MgCl₂, 30 mM DTT, 1 mM each rNTP, 50 nM [α-³²P]UTP, 20 U of RNAse inhibitor (Roche Applied Science, Indianapolis, IN, USA), 60 U of T7 RNA polymerase (Stratagene, La Jolla, CA, USA) and 30 pmol of purified (PCR Cleanup Kit, Qiagen, Valencia, CA, USA) PCR product for 1 h at 37°C in a total reaction volume of 50 µl. The labeled RNA was used in the binding assay without purification. Radiolabeled RNAs (5 µl in each binding reaction) were incubated in 100 µl BB with increasing concentrations of protein. For binding curves, the reactions were passed through individual 0.45 µl HA nitrocellulose filters (Millipore, Billerica, MA, USA) over DE 81 filter paper (Whatman, Florham Park, NJ, USA). In this method, the nitrocellulose filter captures the protein-bound radiolabeled RNA, while the DE81 paper captures unbound radiolabeled RNA. The amount of radioactivity retained at each protein concentration was quantified using a Storm 840 phosphorimager (Amersham Biosciences Corp., Piscataway, NJ, USA) and ImageQuant.

Inhibition of DNA polymerase activity with RNA aptamers

To detect the inhibition of the DNA polymerases, RNA aptamers were preincubated in 10 µl of 50 mM NaCl with DNA polymerase at 37°C for 10 min. Then 10 µl of the solution, containing 1–6 pmol (50–300 nM final concentration) of the oligonucleotide annealed substrate duplex [³²P-S'-GGAA-GAAGAATGATGTT-3' 5'-CCTTCTCTTACATAACA-TACTTTCCTTC-3'] ³²P-labeled and annealed as described (26); 50 mM Tris–HCl (pH 7.5), 10 mM MgCl₂, 10 mM DTT, 2 µg/ml BSA, 10% glycerol and 100 µM dATP, dGTP and dTTP, were added to the DNA–polymerase/aptamer mixture. After 10 min at 37°C, reactions were placed on ice and an equal volume of loading buffer (95% formamide, 0.1% bromphenol blue, 0.1% xylene cyanol and 10 mM EDTA) was added to each tube. The products of the polymerization reaction were separated on a 20% denaturing PAGE and analyzed using a Storm 840 phosphorimager (Amersham Biosciences Corp., Piscataway, NJ, USA) and quantified with ImageQuant. Time course assays were performed similarly except that reaction time varied from 1 to 20 min.

RESULTS AND DISCUSSION

In vitro selection of RNA aptamers that bind polβ

For the selection of RNA aptamers that bind to and inhibit polβ, an RNA library of ~8 x 10¹² different molecules was generated with each molecule containing a 30 nt random sequence flanked by defined sequences as described in the Materials and Methods. Atenators were obtained after four rounds of selection on nitrocellulose filters and three rounds of selection in the wells of immunological plates (Table 1). After seven rounds of selection, the amplified cDNAs were cloned.

Aptamers that inhibit polβ activity

Since our selection was based on a general interaction between the aptamer and polβ, a further level of selection was necessary to distinguish which of these aptamers could inhibit polymerase activity. A total of 60 cloned aptamers were screened in primer extension DNA polymerase assays. To observe the level of inhibition, polβ was pre-incubated with two different concentrations of each individual RNA aptamer. Once equilibrated, a ³²P-labeled primed oligonucleotide substrate and dNTPs were added, and the mixture incubated to permit polβ to extend the primer. A representative gel from the screening of eight individual cloned aptamers showed that at high aptamer concentration (480 nM), all eight aptamers reduced the efficiency of primer extension but only aptamers 32, 25 and 53 inhibited polymerase activity at the 10-fold lower (48 nM) concentration (Figure 1). Aptamer 45 (data not shown) also inhibited polβ at 48 nM. Of the 60 aptamers tested, seven were good inhibitors of polβ (25, 32, 33, 41, 42, 45 and 53), about 35 aptamers slightly inhibited DNA polymerase activity at high concentration...
similar to aptamers 12, 14, 17, 31 and 59, and the other aptamers showed virtually no ability to inhibit the polymerase activity even at high concentrations (data not shown).

**Anti-polβ aptamers also inhibit DNA polymerase κ**

In order to determine the specificity of the polymerase inhibition, the individual aptamers were incubated with polκ in primer extension assays under similar conditions to that used for polβ (Figure 2) except the aptamer concentration was 240 nM. As observed with polβ, aptamers 32, 25 and 53 were the most inhibitory, 12, 14 and 17 were moderately inhibitory and 31 and 59 the least effective at inhibiting polκ activity. Aptamer 45 (data not shown) was also an effective inhibitor of polκ. All other aptamers analyzed had minimal effect on polκ activity and were not analyzed further.

**Sequence of selected aptamers**

Seven strongly inhibitory aptamers and a poor inhibiting aptamer (aptamer 31) were sequenced. The eight aptamers had five different RNA sequences (Figure 3). The most stable two-dimensional structure of each RNA aptamer was predicted using MFOLD program (28,29) (Figure 3). In general, two different folded structures are predicted from the selected 80 nt long aptamer sequences. In 4 of 5 cases, the aptamers form a tri-lobed stem–loop structure with two long loops and a short loop (Aptamers 25, 32, 45, 53). Loop 1 is composed entirely of bases from the 5′ constant region of the aptamer and loops 2 and 3 are formed due to complementarities between the constant and variable regions. All the inhibitory aptamers have loops 1 and 2 which are identical, whereas loop 3 differs among the four aptamers. The other structure (Aptamer 31) is predicted to form a bi-lobed stem–loop structure. Loop 1, being formed from the constant region is also present in Aptamer 31. The structure and sequence of loop 2 is very different from the equivalent loop in the other aptamers and loop 3 is missing. Further mutation studies of these sequences will allow us to determine if the structure or the sequence are more important for binding to and inhibiting the activity of DNA polymerases.

**Affinity of aptamers for DNA polymerases**

To evaluate binding specificities of these aptamers with polβ and polκ, a nitrocellulose binding experiment was performed using 5′-radiolabeled RNAs (Figure 4A and B) and the values of the dissociation constants (KDs) of RNAs were determined (Figure 4C). We found that the aptamers selected for polβ binding also bound polκ with similar affinities (Figure 4B and C). However, the maximum level of binding of aptamers 32 and 45 for polκ are notably lower than that of aptamer 25. Perhaps these aptamers fold into two or more slightly different conformations that interact with polκ with different affinities.

**RNA aptamers compete with primed oligonucleotide substrate for binding**

To elucidate the mode of aptamer binding, we analyzed the ability of the aptamers to displace a bound primed oligonucleotide template. Polβ was incubated with a tight binding 4-base gapped oligonucleotide substrate (27) and varying amounts of RNA aptamer. After a 15 min incubation, the mixture was electrophoresed on a non-denaturing gel. Representative results using aptamer 25 are shown in Figure 5.

However, all aptamers tested (25, 32, 45 and 53) were able to displace the DNA bound in the polymerase active site at similar aptamer concentrations (data not shown).
Anti-polβ aptamers also inhibit other DNA polymerases

To determine if the selected aptamers inhibit DNA polymerases other than polβ and κ, we assayed RB69 DNA polymerase (RB69 pol, family B) and the Klenow fragment of DNA polymerase I (KF, family A) from E.coli in the presence of two inhibitory aptamers, 32 and 45 (Figure 6A). Yeast tRNA (up to 1 mM) only slightly reduced the extension of the primer by polβ and polκ while aptamers 32 and 45 almost completely inhibited the polymerase activity. Aptamers 32 and 45 had a minor inhibitory effect on RB69 pol, the effect being greater with aptamer 45. No inhibitory effect of the aptamers were detected for KF. We also performed a time course experiment showing dramatic inhibition of polβ and κ compared with the tRNA control (Figure 6B) by aptamer 32. In the presence of 1 μM aptamer 32 polβ has 20% remaining activity and polκ, 26% compared with the tRNA control condition. In contrast, we observed no inhibition of KF even at 4-fold higher concentrations of aptamer 32 (Figure 6B). Thus, the selected aptamers are most effective at inhibiting the lower fidelity pols from the X and Y families and have little or no effect on the higher fidelity pols from the A and B families.

Structure of DNA polymerases may explain low specificity of inhibitory aptamers

A number of RNA aptamer structures have been determined by X-ray crystallography or NMR spectroscopy (30). These structural analyses have been useful to generalize two types of aptamers. High affinity aptamers generated against proteins that are potentially nucleic acid-binding proteins are shorter in length and bind to their protein targets through a small number of interaction sites. The major interactions between the RNA and the protein are stacking of flat moieties, hydrogen bonding and shape complementation (30). The aptamers described here appear to bind directly in the polymerase active site, displacing the bound DNA substrate (Figure 5). The Kd's for the polymerase primer-template interactions are as follows: RB69 pol, 70 nM (31), KF, 5 nM (32), polβ, 49 nM (primer-template) (33) and 48 nM (1-base gapped template (34)), and the polκ homolog (Sso DNA pol Y1) has been reported to bind dsDNA with a Kd of 30 nM (35). From these approximate values one can conclude that, among these four polymerases, KF has the strongest interaction with primer-template DNA. If the mechanism by which the aptamer binds the protein and inhibits polymerase
activity requires displacement of the DNA substrate, the tighter DNA binding of KF may partially explain the lack of inhibition by the aptamers. The structures of the binary (DNA–protein) complexes of these DNA polymerases have been determined (36–39) (Figure 7). The interaction of KF with primer-template DNA involves a large number of amino acid residues and the protein wraps around the bound DNA. In the polβ structure, there are fewer interactions and the DNA binding site is more open. RB69 pol and polκ are intermediate between these two extremes. Perhaps a combination of substrate binding affinity and the ‘openness’ of the active site determines whether these tri-lobed aptamers inhibit the polymerase activity.

Comparison with other polymerase inhibiting aptamers

RNA aptamers have been selected that bind and inhibit HIV-1 reverse transcriptase (40–44), yeast RNA polymerase II (45) and E.coli RNA polymerase (46). In general, although it has not been tested extensively, polymerase binding aptamers have been found to be specific. For instance, the HIV-1 RT aptamers did not inhibit the reverse transcriptases from Moloney murine leukemia virus or avian myeloblastosis virus (43). The yeast RNA polymerase II aptamer did not inhibit RNA polymerase I or III (45) and the E.coli RNA polymerase aptamers did not bind to Taq RNA polymerase (46). However, some of the HIV-1 RT inhibitory aptamers...
mimick primer-template junctions and could be extended by the target polymerase RT as well as Sequenase (T7 DNA pol) and AMV RT (47). The co-crystal structure of an RNA pseudoknot bound to HIV-1 RT shows that the position of the RNA aptamer bound to RT largely overlaps the DNA binding site (48). It is likely that the polβ aptamers we describe also occupy the DNA binding site. The low polymerase selectivity of the polβ aptamers offers an advantage over highly specific inhibitory aptamers in that they may be useful as generalized DNA repair suppression molecules. Future experiments are underway to express these aptamer in cells to explore this possibility.

ACKNOWLEDGEMENTS
The authors thank Samuel H. Wilson for the polβ overexpression plasmid and Haruo Ohmori for the bacterial expression plasmid for truncated polk. The authors are indebted to Margaret Luk-Paszyc for helpful discussions and critical reading of the manuscript. This research was supported by grant CA17395 from the National Cancer Institute to APG. Funding to pay the Open Access publication charges for this article was provided by the National Cancer Institute (grant CA17395).

Conflict of interest statement. None declared.

REFERENCES

1. Albertella, M.R., Lau, A. and O’Connor, M.J. (2005) The overexpression of specialized DNA polymerases in cancer. DNA Repair, 4, 583–593.
2. Wilson, S.H. (1998) Mammalian base excision repair and DNA polymerase beta. Mutat. Res., 407, 203–215.
3. Abbotts, J., SenGupta, D.N., Zmudzka, B., Widen, S.G., Notario, V. and Wilson, S.H. (1988) Expression of human DNA polymerase beta in Escherichia coli and characterization of the recombinant enzyme. Biochemistry, 27, 901–909.
4. Singhal, R.K. and Wilson, S.H. (1993) Short gap-filling synthesis by DNA polymerase beta is processive. J. Biol. Chem., 268, 15906–15911.
5. Husain, I., Morton, B.S., Beard, W.A., Singhal, R.K., Prasad, R., Wilson, S.H. and Besterman, J.M. (1995) Specific inhibition of DNA polymerase beta by its 14 kDa domain: role of single- and double-stranded DNA binding and 5’-phosphate recognition. Nucleic Acids Res., 23, 1597–1603.
6. Bhattacharyya, N., Chen, H.C., Wang, L. and Banerjee, S. (2002) Heterogeneity in expression of DNA polymerase beta and DNA repair activity in human tumor cell lines. Gene Expr., 10, 115–123.
7. Thompson, T.E., Rogan, P.K., Risinger, J.I. and Taylor, J.A. (2002) Splice variants but not mutations of DNA polymerase beta are common in bladder cancer. Cancer Res., 62, 3251–3256.
8. Canitrot, Y., Cazaux, C., Frechet, M., Bouayadi, K., Lesca, C., Salles, B. and Hoffmann, J.S. (1998) Overexpression of DNA polymerase beta in cell results in a mutator phenotype and a decreased sensitivity to anticancer drugs. Proc. Natl Acad. Sci. USA, 95, 12586–12590.
9. Bergoglio, V., Pillaire, M.J., Lacroix-Triki, M., Raynaud-Messina, B., Canitrot, Y., Bieth, A., Gares, M., Wright, M., Delsol, G., Loeb, L.A. et al. (2002) Deregulated DNA polymerase beta induces chromosome instability and tumorigenesis. Cancer Res., 62, 3511–3514.
10. Servant, L., Cazaux, C., Bieth, A., Iwai, S., Hanaoka, F. and Hoffmann, J.-S. (2002) A role for DNA polymerase beta in mutagenic UV lesion bypass. J. Biol. Chem., 277, 50046–50053.
11. Bergoglio, V., Canitrot, Y., Hogarth, L., Minto, L., Howell, S.B., Cazaux, C. and Hoffmann, J.S. (2001) Enhanced expression and activity of DNA polymerase beta in human ovarian tumor cells: impact on sensitivity towards antitumor agents. Oncogene, 20, 6181–6187.
12. Raaphorst, G.P., Cybulski, S.E., Sobol, R. and Ng, C.E. (2001) The response of human breast tumour cell lines with altered polymerase beta levels to cisplatin and radiation. Anticancer Res., 21, 2079–2083.

Figure 7. Comparison of the DNA binding modes for DNA polymerase. Polβ binary complex (Protein Data Bank accession code 1BPX), DPO4 binary complex (as a family Y model structure) (1N56), RB69 pol binary complex (1Q9X), KF (Bacillus) binary complex (1L3S). The protein residues are shown in a gray surface representation, the DNA primer strand in green and the template in dark blue. Figure was generated using PyMOL (50) (http://www.pymol.org).
13. Woodgate,R. (1999) A plethora of lesion-replicating DNA polymerases. Genes Dev., 13, 2191–2195.
14. Ohmori,H., Friedberg,E.C., Fuchs,R.P., Goodman,M.F., Hanaoka,F., Hinkle,D., Kunke1,T.A., Lawrence,C.W., Livneh,Z., Nohmi,T. et al. (2001) The Y-family of DNA polymerases. Mol. Cell, 8, 7–8.
15. Ellington,A.D. and Szostak,J.W. (1990) In vitro selection of RNA molecules that bind specific ligands. Nature, 346, 818–822.
16. Tuerk,C. and Gold,L. (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 249, 505–510.
17. Held,D.M., Kissel,J.D., Patterson,J.T., Nickens,D.G. and Burke,D.H. (2000) HIV-1 inactivation by nucleic acid aptamers. Front. Biosci., 11, 89–112.
18. Nickens,D.G., Patterson,J.T. and Burke,D.H. (2003) Inhibition of HIV-1 reverse transcriptase by RNA aptamers in Escherichia coli. RNA, 9, 1029–1033.
19. Joshi,P.J., Fisher,T.S. and Prasad,V.R. (2003) Anti-HIV inhibitors based on nucleic acids: emergence of aptamers as potent antivirals. Curr. Drug Targets Infect. Disord., 3, 383–400.
20. Sooter,L.J., Riedel,T., Davidson,E.A., Levy,M., Cox,J.C. and Ellington,A.D. (2001) Toward automated nucleic acid enzyme selection. Biol. Chem., 382, 1327–1334.
21. Conlon,K.A., Miller,H., Rosenquist,T.A., Zharkov,D.O. and Berrios,M. (2005) The murine DNA glycosylase NEIL2 (mNEIL2) and human DNA polymerase beta bind microtubules in situ and in vitro. DNA Repair, 4, 419–431.
22. Ohashi,E., Ogii,T., Kusumoto,R., Iwai,S., Masutani,C., Hanaoka,F. and Ohmori,H. (2000) Error-prone bypass of certain DNA lesions by the DNA polymerase beta misincorporates nucleotides: evidence for a role for the flexible loop in DNA positioning within the active site. J. Biol. Chem., 275, 577–584.
23. Ellington,A.D. and Szostak,J.W. (1990) Synthesis of RNA molecules that bind specific ligands. Proc. Natl Acad. Sci. USA, 87, 8410–8417.
24. Chenna,R., Sugawara,H., Koike,T., Lopez,R., Gibson,T.J., Thompson,J.D. and Higgins,D.G. (2003) Multiple sequence alignment with the Clustal series of programs. EMBO J., 22, 4094–4100.
25. Miller,H., Prasad,R., Wilson,S.H., Kraut,J. and Pelletier,H. (1997) Crystal structures of human DNA polymerase beta complexed with gapped and nicked DNA: evidence for an induced fit mechanism. Biochemistry, 36, 11205–11215.
26. Ling,H., Boudsocq,F., Woodgate,R. and Yang,W. (2004) Snapshots of replication through an abasic lesion; structural basis for base substitutions and frameshifts. Mol. Cell, 13, 751–762.
27. Dahlberg,M. and Benkovic,S.J. (1992) Kinetic characterization of the Klenow fragment exo-) activity on damaged DNA templates: effect of processivity factors PCNA and RFC. J. Biol. Chem., 277, 47394–47401.
28. Ohmori,H. (2000) Error-prone bypass of certain DNA lesions by the DNA polymerase beta misincorporates nucleotides: evidence for a role for the flexible loop in DNA positioning within the active site. J. Biol. Chem., 275, 89–96.
29. Ellington,A.D. and Szostak,J.W. (1990) Synthesis of RNA molecules that bind specific ligands. Proc. Natl Acad. Sci. USA, 87, 8410–8417.
30. Chenna,R., Sugawara,H., Koike,T., Lopez,R., Gibson,T.J., Thompson,J.D. and Higgins,D.G. (2003) Multiple sequence alignment with the Clustal series of programs. EMBO J., 22, 4094–4100.
31. Miller,H. and Grollman,A.P. (1997) Kinetics of DNA polymerase I (Klenow fragment exo-) activity on damaged DNA templates: effect of proximal and distal template damage on DNA synthesis. Biochemistry, 36, 15336–15342.
32. Miller,H., Prasad,R., Wilson,S.H., Johnson,F. and Grollman,A.P. (2000) 8-oxodGTP incorporation by DNA polymerase beta is modified by active- site residue Asn279. Biochemistry, 39, 1029–1033.
33. Zuker,M. (2003) Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res., 31, 3406–3415.
34. Mathews,D.H., Sabina,J., Zuker,M. and Turner,D.H. (1999) Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J. Mol. Biol., 288, 911–940.
35. Thomas,M., Chedin,S., Carles,C., Riva,M., Manolakos and Sentenac,A. (1997) Selective targeting and inhibition of yeast RNA polymerases. J. Biol. Chem., 272, 27980–27986.
36. Kulbachinsky,A., Feklistov,A., Krasleninikov,I., Goldfarb,A. and Nikiforov,V. (2004) Aptamers to Escherichia coli core RNA polymerase that sense its interaction with rifampicin, sigma-subunit and GreB. Eur. J. Biochem., 271, 4921–4931.
37. Schneider,D.J., Feigon,J., Hostomsky,Z. and Gold,L. (1995) High-affinity ssDNA inhibitors of the reverse transcriptase of type 1 human immunodeficiency virus. Biochemistry, 34, 9599–9610.
38. Jaeger,J., Restle,T. and Steitz,T.A. (1998) The structure of HIV-1 reverse transcriptase complexed with an RNA pseudoknot inhibitor. EMBO J., 17, 4535–4542.
39. Chenna,R., Sugawara,H., Koike,T., Lopez,R., Gibson,T.J., Higgins,D.G. and Thompson,J.D. (2003) Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res., 31, 3497–3500.
40. DeLano,W.L. (2002) The PyMOL Molecular Graphics System.